Pleasanton, CA, United States of America

Raffaella Faggioni

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 9.5

ph-index = 5

Forward Citations = 146(Granted Patents)


Location History:

  • Pleasanton, CA (US) (2007 - 2012)
  • Gaithersburg, MD (US) (2021 - 2022)

Company Filing History:


Years Active: 2007-2022

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):

Title: Innovator Spotlight: Raffaella Faggioni

Introduction

Raffaella Faggioni is a prominent inventor based in Pleasanton, California, recognized for her significant contributions to the field of biomedical research. With a remarkable portfolio of 8 patents, she focuses on advancing therapeutic strategies for patients suffering from interleukin-23 (IL23)-mediated diseases, including Crohn's disease. Her innovative work highlights the intersection of molecular biology and clinical application.

Latest Patents

Among Raffaella's latest patents is a groundbreaking invention titled "CCL20 as a predictor of clinical response to IL23-antagonists." This invention employs the Chemokine (C-C motif) ligand 20 (CCL20) as a biomarker to stratify patient populations suffering from IL23-mediated diseases. The use of CCL20 allows for the assessment of patient eligibility for treatment with anti-IL23 antagonists, guiding clinical decision-making on whether to commence, suspend, or modify therapeutic interventions. Additionally, her other recent patent, "Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers," describes utilizing components of the IL23 pathway—such as IL22 and lipocalin-2 (LCN2)—to effectively identify patients responsive to anti-IL23 therapies.

Career Highlights

Raffaella has built a distinguished career, including her tenure at reputable companies such as Amgen Fremont Inc. and Amgen Inc. Her expertise in developing biomarkers and therapeutic approaches has greatly impacted the way IL23-mediated diseases are treated in clinical settings. Her contributions are pivotal in enhancing patient care through tailored treatments based on biomarker assessments.

Collaborations

Throughout her career, Raffaella has collaborated with several notable individuals, including her coworkers Orit Foord and Scott L Klakamp. These partnerships have fostered an environment of innovation, enabling the successful development and patenting of new medical technologies.

Conclusion

Raffaella Faggioni is a trailblazer in the realm of biomedical innovation. With an impressive array of patents and a commitment to enhancing patient outcomes, she exemplifies the impact of dedicated inventors in the life sciences. As research continues to evolve, Raffaella’s work will undoubtedly contribute to significant advancements in therapeutic strategies for managing chronic diseases like Crohn's disease.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…